Tumor-infiltrating lymphocytes (TILs)—including CD8+ and CD4+ T-cells, regulatory T-cells (Tregs), and B-cells (CD20+)—constitute a key element of anti-tumor immune surveillance. The gene discussed is CD4; the disease is neoplasm.